Filing Flows › Alamar Biosciences (ALMR) › Guidance & outlook

Alamar Biosciences (ALMR) guidance and outlook

Alamar Biosciences (ALMR) raised its guidance on Nov 3, 2026: Revenue $121M–$123M for FY2026; Revenue +64% for FY2026. Alamar Biosciences' 10-Q filed Nov 4, 2026 makes 42 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 3, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 4, 2026

• We are also developing a second instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027.
• Our research and development efforts focus on developing new panels of assays to target an expanding menu of protein targets; improving the performance of our existing assays and software; developing new ARGO instrument solutions, including the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027; enhancing and expanding the capabilities of the ARGO HT…
• We expect to continue to incur significant expenses and operating losses in the near term as we invest in the continued growth of our business to include increasing headcount required to develop, sell, and support our platforms, scale our technology platform and introduce new products and services, protect and defend our intellectual property and potentially acquire new businesses or technologies.
• In addition, we expect to continue to incur additional costs associated with operating as a public company, including significant legal, audit, accounting, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer liability insurance costs, investor and public relations costs, and other expenses that we did not incur as a private…
• We believe that these metrics are representative of our current business; however, we anticipate these may change or may be substituted for additional or different metrics as our business evolves and as we introduce new products.
• Our goal is to continue to grow the instrument installed base and we expect to evaluate and report changes to our instrument installed base on an annual basis.
• We believe that our financial performance has been and in the foreseeable future will continue to be primarily driven by the following factors.
• Our financial performance has been, and is expected to continue to be, significantly influenced by the rate of sales of our ARGO HT instruments.
• We expect instrument sales to grow as we deepen penetration in existing markets and expand into new markets, including through the introduction of new instruments, features and solutions, and new assays to run on the platform.
• We plan to drive instrument sales growth through several strategies, including expanding our global sales organization, introducing new instruments, and continuing to enhance the underlying technology and applications that support life sciences research, as well as entering into new disease markets.
• In addition, we are developing future instruments designed to support the full continuum of discovery, translational research, and diagnostics, which we believe will expand our addressable market and increase utilization among customers, if approved.
• As a result of this variability, we have experienced, and expect to continue to experience, period-to-period fluctuations in instrument sales.

Alamar Biosciences' latest quarter

Questions

Did Alamar Biosciences raise or lower its guidance?

Alamar Biosciences (ALMR) raised its guidance on Nov 3, 2026: Revenue $121M–$123M for FY2026; Revenue +64% for FY2026.

What does Alamar Biosciences expect?

We are also developing a second instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. Our research and development efforts focus on developing new panels of assays to target an expanding menu of protein targets; improving the performance of our existing assays and software; developing new ARGO instrument solutions, including the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027; enhancing and expanding the capabilities o

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.